The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic stem cell transplantation (HSCT) for individuals with myelodysplastic syndromes (MDS) based on requests from ASH, ASTCT, NMDP, and CIBMTR.

Efficient, Accurate Risk Stratification Will Transform Patient Care

Friendly Community Walks to Advance Awareness & Accelerate Research for Myelodysplastic Syndromes - a Rare Blood Cancer